The incidence of type I galactosemia is around 1 in every 60,000 newborns, while type II affects fewer than 1 in 100,000 newborns and type III affects fewer still. Symptoms.

In the phase III ACTION-Galactosemia Kids study in children with ... Allogene Therapeutics’ estimates for loss per share have narrowed from $1.40 to $1.35 for 2024, and that for 2025 has ...

It’s easy to test for galactosemia. It’s also simple to treat once it’s diagnosed. And children who have it can live normal lives. Type I occurs in about 1 in every 30,000 to 60,000 people.

Concretely, galactosemia is a rare genetic disorder caused by a lack of the enzyme galactose-1-phosphate uridylyltransferase [GALT] for metabolizing galactose, a sugar component of lactose present ...

Galactosemia is a rare genetic, metabolic disorder caused by a deficiency in the galactose-1-phosphate uridyltransferase (GALT). This means patients cannot break down galactose, causing a buildup ...

The US Food and Drug Administration (FDA) has declined to approve Applied Therapeutics’ govorestat for classic galactosemia, prolonging the wait for the first marketed treatment for the genetic ...

The NDA for govorestat for the galactosemia indication was accepted ... estimates for Illumina’s 2024 EPS have moved up from $1.84 to $3.63. The consensus estimate for 2025 earnings has improved ...

Applied Therapeutics, Inc.'s stock surged nearly 70% yesterday after the news that the FDA will not hold an AdCom to discuss approval of AT-007 in galactosemia. AT-007 has shown clinical benefits ...

The NDA included data from the phase 1/2 ACTION-Galactosemia study (ClinicalTrial.gov Identifier: NCT04117711) and the phase 3 ACTION-Galactosemia Kids trial (ClinicalTrial.gov Identifier ...

Galactosemia affects around 1 in every 60,000 infants of European origin. The condition is caused by a mutation in the gene that codes for the GALT enzyme.